Switch to Upadacitinib or Risankizumab
For patients on maximum dose of their current IBD therapy, switch to upadacitinib (for ulcerative colitis) or risankizumab (for Crohn's disease) as these agents demonstrate the highest efficacy in biologic-exposed patients with the lowest rates of secondary loss of response.
Disease-Specific Recommendations
For Ulcerative Colitis
First-line switch options (HIGHER efficacy tier):
- Upadacitinib - Most effective in TNF-exposed patients, with sustained response rates and oral convenience 1
- Tofacitinib - Alternative JAK inhibitor if upadacitinib unavailable
- Ustekinumab - Strong efficacy in biologic-exposed patients 1
Second-line options (INTERMEDIATE efficacy tier):
- Filgotinib, mirikizumab, risankizumab, or guselkumab 1
Key consideration: The 2024 AGA guidelines specifically recommend HIGHER or INTERMEDIATE efficacy medications over LOWER efficacy options (adalimumab, vedolizumab, ozanimod, etrasimod) in patients previously exposed to advanced therapies 1.
For Crohn's Disease
First-line switch options:
- Risankizumab - Highest efficacy in biologic-exposed patients with superior endoscopic remission rates 2, 3
- Upadacitinib - Particularly effective after TNF failure 2, 3
- Guselkumab - IL-23p19 antagonist with high efficacy in refractory disease 3
Second-line options:
- Ustekinumab - Strong recommendation for patients failing TNF therapy 4, 5
- Vedolizumab - Effective but may be less so in heavily pre-treated patients 4
Critical insight from network meta-analysis: In biologic-exposed CD patients, risankizumab, guselkumab, upadacitinib, and adalimumab (in specific contexts) demonstrate significantly higher efficacy than vedolizumab and mirikizumab 3.
Why These Agents Have Lower Loss of Response
Mechanism-Based Durability
JAK inhibitors (upadacitinib, tofacitinib):
- Small molecules with no immunogenicity risk
- No antibody formation = no pharmacokinetic loss of response
- Particularly potent in TNF-exposed patients due to IL-6-JAK-STAT pathway activation 3
IL-23p19 antagonists (risankizumab, guselkumab):
- Target chronic inflammation pathways upregulated after TNF failure
- Molecular evidence shows IL-23 receptor upregulation in TNF-refractory tissue 3
- Superior endoscopic remission maintenance in head-to-head comparison (risankizumab vs ustekinumab: 48-week endoscopic remission significantly higher) 2
Evidence for Sustained Response
The SEQUENCE study demonstrated risankizumab's superiority over ustekinumab for endoscopic remission at week 48 in anti-TNF treated patients, indicating better durability 2. For upadacitinib, maintenance data shows 37.3% (15mg) to 47.6% (30mg) clinical remission at 52 weeks versus 15.1% placebo 2.
Practical Implementation Algorithm
Step 1: Confirm maximum dosing of current therapy
- Use therapeutic drug monitoring if on biologic
- Document adequate drug levels with ongoing symptoms
Step 2: Assess prior exposure history
- TNF-exposed patients → prioritize upadacitinib (UC) or risankizumab (CD)
- Multiple biologic failures → strongly favor JAK inhibitors or IL-23p19 antagonists
Step 3: Screen for contraindications
- JAK inhibitors: Age >65, cardiovascular disease, smoking history, prior malignancy, VTE risk 1
- IL-23 antagonists: Generally favorable safety profile across populations
Step 4: Evaluate response timeline
- Upadacitinib/tofacitinib: Assess at 8-12 weeks 1
- Risankizumab/guselkumab: Assess at 12-16 weeks 2
- Ustekinumab: Assess at 6-10 weeks (CD) 4
Critical Pitfalls to Avoid
Don't switch within the same class after maximum dose failure - Switching between TNF antagonists when already on maximum dose shows poor outcomes 4. Move to different mechanism of action.
Don't delay switching - Prolonged exposure to failing therapy increases complications, hospitalizations, and surgery risk 1.
Don't ignore regulatory restrictions - JAK inhibitors have FDA restrictions for first-line use in advanced therapy-naïve patients; they're specifically indicated for TNF-failure 1.
Don't continue combination immunomodulator therapy unnecessarily - When switching from TNF antagonist, reassess need for thiopurine continuation given increased lymphoma risk with combination therapy 6.
Special Populations
Older patients (>60 years): Prefer vedolizumab or IL-23 antagonists over JAK inhibitors due to cardiovascular and malignancy concerns 1.
Women of childbearing age: Avoid JAK inhibitors and S1P modulators due to limited pregnancy safety data 1.
High infection risk: Prefer vedolizumab or IL-23 antagonists (gut-selective or lower systemic immunosuppression) 1.